Latest Comments

23andMe: bringing early diagnosis of Type 1 Gaucher disease one step closer?

23andMe: bringing early diagnosis of Type 1 Gaucher disease one step closer?

PCR-based C. difficile Cytotoxin assays alone not appropriate for pivotal endpoint measures

PCR-based C. difficile Cytotoxin assays alone not appropriate for pivotal endpoint measures

Newest class of type 2 diabetes drugs continues its push into the US market

Newest class of type 2 diabetes drugs continues its push into the US market

China’s pharma market transformation to fuel global industry growth

China’s pharma market transformation to fuel global industry growth

WHO’s first global hepatitis report aims high: elimination of hepatitis B and C by 2030

WHO’s first global hepatitis report aims high: elimination of hepatitis B and C by 2030

More than just a pretty face: Botox set to combat depression

More than just a pretty face: Botox set to combat depression

Recurring C. difficile infections cause havoc in hospitals in Scotland and England

Recurring C. difficile infections cause havoc in hospitals in Scotland and England

Curing hepatitis C: A double-edged sword for liver transplant candidates?

Curing hepatitis C: A double-edged sword for liver transplant candidates?

Small but mighty: nanotechnology in cancer therapy

Small but mighty: nanotechnology in cancer therapy

Pharma price hiking: why does it happen?

Pharma price hiking: why does it happen?

Mundipharma to market Invossa in Korea, marking another strategic partnership for Kolon Life Science

Mundipharma to market Invossa in Korea, marking another strategic partnership for Kolon Life Science

Targeting of specific patient groups to break into the epilepsy market

Targeting of specific patient groups to break into the epilepsy market

Uncertainty Grows for Immuno-Oncology Therapies in Glioblastoma Multiform

Uncertainty Grows for Immuno-Oncology Therapies in Glioblastoma Multiform

Heading for the future: transplants and the pharma market

Heading for the future: transplants and the pharma market

Supernus Pharmaceuticals expands neurology portfolio with label extension of Trokendi XR

Supernus Pharmaceuticals expands neurology portfolio with label extension of Trokendi XR

PhRMA puts blame squarely on insurers in new drug spending report

PhRMA puts blame squarely on insurers in new drug spending report

Novo Nordisk’s Refixia: what are its prospects in the hemophilia B space?

Novo Nordisk’s Refixia: what are its prospects in the hemophilia B space?

Roche expected to remain an ovarian cancer drug market leader

Roche expected to remain an ovarian cancer drug market leader

FDA raises warning flag over Viberzi safety in IBS-D

FDA raises warning flag over Viberzi safety in IBS-D

Inclisiran: a novel approach to targeting cholesterol and patient needs

Inclisiran: a novel approach to targeting cholesterol and patient needs

Roche’s Ocrevus expected to be a game-changer for the multiple sclerosis market

Roche’s Ocrevus expected to be a game-changer for the multiple sclerosis market